ALK and neoplasm: Tecentriq is currently used in combination with Avastin (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of individuals with metastatic NSCLC with no EGFR or ALK genomic tumor aberrations.